Brilinta (ticagrelor) added to american college of chest physicians recommendations on antithrombotic therapy and prevention of thrombosis

AstraZeneca, 02/22/2012

AstraZeneca announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation for giving the oral antiplatelet medicine, BRILINTA (ticagrelor) tablets with low–dose aspirin to patients who suffer from Acute Coronary Syndrome (ACS).

Print Article Summary Cat 2 CME Report